ADMA Biologics Stock Price, News & Analysis (NASDAQ:ADMA)

$2.85 -0.35 (-10.94 %)
(As of 11/18/2017 11:12 AM ET)
Previous Close$2.85
Today's Range$3.29 - $2.75
52-Week Range$2.01 - $6.10
Volume479,413 shs
Average Volume245,003 shs
Market Capitalization$73.51 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics logoADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:ADMA
  • CUSIP: N/A
  • Web: www.admabiologics.com
Debt:
  • Debt-to-Equity Ratio: 2.26%
  • Current Ratio: 2.36%
  • Quick Ratio: 1.35%
Sales & Book Value:
  • Annual Sales: $10.66 million
  • Price / Sales: 6.90
  • Book Value: $0.50 per share
  • Price / Book: 5.70
Profitability:
  • Trailing EPS: ($0.82)
  • Net Income: ($19,510,000.00)
  • Net Margins: -35.00%
  • Return on Equity: -76.26%
  • Return on Assets: -9.77%
Misc:
  • Employees: 92
  • Outstanding Shares: 25,790,000
 

Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings data on Friday, August, 11th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.29. The biotechnology company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $3.52 million. ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%. View ADMA Biologics' Earnings History.

When will ADMA Biologics make its next earnings announcement?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Friday, February, 23rd 2018. View Earnings Estimates for ADMA Biologics.

Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?

2 analysts have issued 1-year target prices for ADMA Biologics' shares. Their forecasts range from $5.00 to $13.00. On average, they expect ADMA Biologics' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for ADMA Biologics.

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:

  • Steven A. Elms, Chairman of the Board (Age 53)
  • Adam S. Grossman, President, Chief Executive Officer, Director (Age 38)
  • Jerrold B. Grossman D.P.S, Vice Chairman of the Board (Age 67)
  • Brian Lenz, Chief Financial Officer (Age 43)
  • James Mond M.D., Ph.D., Chief Scientific and Medical Officer (Age 69)
  • Bernhard R. M. Ehmer, Director (Age 62)
  • Bryant E. Fong, Independent Director
  • Dov A. Goldstein M.D., Independent Director (Age 49)
  • Lawrence P. Guiheen, Independent Director (Age 64)
  • Eric I. Richman, Independent Director (Age 55)

Who owns ADMA Biologics stock?

ADMA Biologics' stock is owned by many different of institutional and retail investors. Top institutional investors include AISLING CAPITAL II LP (8.00%) and Iguana Healthcare Management LLC (2.19%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.

Who bought ADMA Biologics stock? Who is buying ADMA Biologics stock?

ADMA Biologics' stock was bought by a variety of institutional investors in the last quarter, including Iguana Healthcare Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.

How do I buy ADMA Biologics stock?

Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA Biologics stock can currently be purchased for approximately $2.85.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $73.51 million and generates $10.66 million in revenue each year. The biotechnology company earns ($19,510,000.00) in net income (profit) each year or ($0.82) on an earnings per share basis. ADMA Biologics employs 92 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]


MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for ADMA Biologics (NASDAQ:ADMA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (215.79% upside)

Consensus Price Target History for ADMA Biologics (NASDAQ:ADMA)

Price Target History for ADMA Biologics (NASDAQ:ADMA)

Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$5.00N/AView Rating Details
6/28/2017Maxim GroupReiterated RatingBuy$13.00MediumView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for ADMA Biologics (NASDAQ:ADMA)

Earnings by Quarter for ADMA Biologics (NASDAQ:ADMA)

Earnings History by Quarter for ADMA Biologics (NASDAQ ADMA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2018        
8/11/2017Q2 2017($0.26)($0.55)$3.52 million$3.40 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.28)($0.51)$3.35 million$2.63 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.42)($0.34)$2.32 million$2.94 millionViewN/AView Earnings Details
8/12/2016Q2($0.39)($0.50)$2.35 million$2.27 millionViewN/AView Earnings Details
5/13/2016Q1($0.37)($0.43)$2.48 million$2.12 millionViewN/AView Earnings Details
11/10/2015Q315($0.39)($0.48)$1.50 million$1.85 millionViewN/AView Earnings Details
8/11/2015Q215($0.32)($0.37)$1.50 million$1.30 millionViewN/AView Earnings Details
5/12/2015Q115($0.32)($0.37)$1.50 million$1.50 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.38)($0.38)$1.52 million$1.41 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.37)($0.36)$1.37 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ ADMA)

Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 34.55%
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Insider Trades by Quarter for ADMA Biologics (NASDAQ ADMA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2017Adam S GrossmanInsiderBuy485,000$2.15$1,042,750.00View SEC Filing  
11/9/2017Brian LenzCFOBuy6,500$2.15$13,975.00View SEC Filing  
11/9/2017Eric I RichmanDirectorBuy25,000$2.15$53,750.00View SEC Filing  
11/9/2017James MondCMOBuy10,000$2.15$21,500.00View SEC Filing  
5/3/2016Adam S GrossmanCEOBuy200,000$6.50$1,300,000.00View SEC Filing  
5/3/2016Brian LenzCFOBuy2,500$6.50$16,250.00View SEC Filing  
5/3/2016James MondCMOBuy770$6.50$5,005.00View SEC Filing  
5/3/2016Jerrold B GrossmanDirectorBuy45,769$6.50$297,498.50View SEC Filing  
12/8/2015Adam S. GrossmanCEOBuy500$9.00$4,500.00View SEC Filing  
12/7/2015Jerrold B GrossmanDirectorBuy500$9.01$4,505.00View SEC Filing  
12/2/2015Adam S GrossmanCEOBuy2,250$9.15$20,587.50View SEC Filing  
12/2/2015Brian LenzCFOBuy1,000$9.15$9,150.00View SEC Filing  
12/2/2015Jerrold B GrossmanDirectorBuy6,000$9.16$54,960.00View SEC Filing  
12/1/2015Adam S GrossmanCEOBuy1,800$9.17$16,506.00View SEC Filing  
11/25/2015Adam S GrossmanCEOBuy1,800$9.18$16,524.00View SEC Filing  
11/20/2015Adam S GrossmanCEOBuy3,861$9.21$35,559.81View SEC Filing  
3/19/2015Adam S GrossmanCEOBuy2,000$8.50$17,000.00View SEC Filing  
3/17/2015Adam S GrossmanCEOBuy5,500$7.98$43,890.00View SEC Filing  
3/17/2015Jerrold B GrossmanDirectorBuy500$8.01$4,005.00View SEC Filing  
3/16/2015Adam S GrossmanCEOBuy8,800$8.03$70,664.00View SEC Filing  
3/16/2015James MondCMOBuy1,250$8.02$10,025.00View SEC Filing  
3/16/2015Lawrence P GuiheenDirectorBuy1,000$7.96$7,960.00View SEC Filing  
3/13/2015Eric I RichmanDirectorBuy3,500$7.88$27,580.00View SEC Filing  
9/12/2014Adam S GrossmanCEOBuy4,300$9.57$41,151.00View SEC Filing  
8/22/2014Adam S GrossmanCEOBuy1,000$9.50$9,500.00View SEC Filing  
8/14/2014Adam S GrossmanCEOBuy2,100$9.77$20,517.00View SEC Filing  
6/18/2014Adam S GrossmanCEOBuy1,875$9.59$17,981.25View SEC Filing  
5/22/2014Adam S GrossmanCEOBuy4,226$8.15$34,441.90View SEC Filing  
5/15/2014Adam S GrossmanCEOBuy13,400$7.50$100,500.00View SEC Filing  
5/14/2014Brian LenzCFOBuy1,000$7.50$7,500.00View SEC Filing  
5/14/2014James MondCMOBuy1,315$7.60$9,994.00View SEC Filing  
12/10/2013Jerrold B GrossmanDirectorBuy3,650$7.30$26,645.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ADMA Biologics (NASDAQ ADMA)

Source:
DateHeadline
Zacks: Analysts Set $8.88 Target Price for ADMA Biologics Inc (ADMA)Zacks: Analysts Set $8.88 Target Price for ADMA Biologics Inc (ADMA)
www.americanbankingnews.com - November 17 at 7:16 PM
$6.68 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter$6.68 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - November 17 at 12:14 PM
ADMA Biologics (ADMA) Reports Newly Issued U.S. Patent for Immunotherapeutic CompositionsADMA Biologics (ADMA) Reports Newly Issued U.S. Patent for Immunotherapeutic Compositions
www.streetinsider.com - November 16 at 10:46 AM
Zacks: Brokerages Expect ADMA Biologics Inc (ADMA) to Announce -$0.55 EPSZacks: Brokerages Expect ADMA Biologics Inc (ADMA) to Announce -$0.55 EPS
www.americanbankingnews.com - November 15 at 7:14 AM
ADMA Biologics Inc (ADMA) Rating Increased to Outperform at Raymond James Financial, Inc.ADMA Biologics Inc (ADMA) Rating Increased to Outperform at Raymond James Financial, Inc.
www.americanbankingnews.com - November 14 at 11:08 AM
Brian Lenz Acquires 6,500 Shares of ADMA Biologics Inc (ADMA) StockBrian Lenz Acquires 6,500 Shares of ADMA Biologics Inc (ADMA) Stock
www.americanbankingnews.com - November 13 at 8:20 PM
Insider Buying: ADMA Biologics Inc (ADMA) CMO Purchases 10,000 Shares of StockInsider Buying: ADMA Biologics Inc (ADMA) CMO Purchases 10,000 Shares of Stock
www.americanbankingnews.com - November 13 at 7:52 PM
ADMA Biologics Inc (ADMA) Director Buys $53,750.00 in StockADMA Biologics Inc (ADMA) Director Buys $53,750.00 in Stock
www.americanbankingnews.com - November 13 at 6:52 PM
ADMA Biologics Announces Closing of $42M Follow-On OfferingADMA Biologics Announces Closing of $42M Follow-On Offering
finance.yahoo.com - November 13 at 6:10 PM
ADMA: Third Quarter 2017 Financial Results and Corporate UpdateADMA: Third Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - November 13 at 6:10 PM
Adam S. Grossman Buys 485,000 Shares of ADMA Biologics Inc (ADMA) StockAdam S. Grossman Buys 485,000 Shares of ADMA Biologics Inc (ADMA) Stock
www.americanbankingnews.com - November 13 at 4:21 PM
Head to Head Analysis: ADMA Biologics (ADMA) & Array BioPharma (ARRY)Head to Head Analysis: ADMA Biologics (ADMA) & Array BioPharma (ARRY)
www.americanbankingnews.com - November 12 at 10:06 PM
Are ADMA Biologics Inc’s (ADMA) Interest Costs Too High?Are ADMA Biologics Inc’s (ADMA) Interest Costs Too High?
finance.yahoo.com - November 10 at 4:05 PM
ADMA Biologics (ADMA) Prices Follow-On OfferingADMA Biologics (ADMA) Prices Follow-On Offering
www.streetinsider.com - November 10 at 8:24 AM
BRIEF-Adma Biologics prices follow-on offering of 17.0 mln sharesBRIEF-Adma Biologics prices follow-on offering of 17.0 mln shares
www.reuters.com - November 9 at 9:27 PM
ADMA Biologics Announces Pricing of Follow-On OfferingADMA Biologics Announces Pricing of Follow-On Offering
finance.yahoo.com - November 9 at 4:25 PM
BRIEF-ADMA Biologics now sees offering‍ of 13.6 mln shares of common stock - SEC filingBRIEF-ADMA Biologics now sees offering‍ of 13.6 mln shares of common stock - SEC filing
www.reuters.com - November 9 at 3:29 AM
ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:24 PM
Zacks Investment Research Analysts Cut Earnings Estimates for ADMA Biologics Inc (ADMA)Zacks Investment Research Analysts Cut Earnings Estimates for ADMA Biologics Inc (ADMA)
www.americanbankingnews.com - November 8 at 12:50 PM
ETFs with exposure to ADMA Biologics, Inc. : November 7, 2017ETFs with exposure to ADMA Biologics, Inc. : November 7, 2017
finance.yahoo.com - November 7 at 4:58 PM
BRIEF-ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30BRIEF-ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30
www.reuters.com - November 4 at 4:59 PM
ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 3 at 8:24 PM
Adma Biologics posts 3Q profitAdma Biologics posts 3Q profit
finance.yahoo.com - November 3 at 8:24 PM
ADMA Biologics Inc (ADMA) Scheduled to Post Earnings on WednesdayADMA Biologics Inc (ADMA) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:08 AM
Why ADMA Biologics Inc (ADMA) Could Be A BuyWhy ADMA Biologics Inc (ADMA) Could Be A Buy
finance.yahoo.com - October 27 at 5:35 PM
Zacks: Brokerages Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $6.86 MillionZacks: Brokerages Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $6.86 Million
www.americanbankingnews.com - October 27 at 9:38 AM
-$0.51 Earnings Per Share Expected for ADMA Biologics Inc (ADMA) This Quarter-$0.51 Earnings Per Share Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - October 25 at 7:08 PM
ETFs with exposure to ADMA Biologics, Inc. : October 25, 2017ETFs with exposure to ADMA Biologics, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 4:16 PM
BRIEF-Adma Biologics Inc files for offering of up to $28.75‍ million of common stockBRIEF-Adma Biologics Inc files for offering of up to $28.75‍ million of common stock
www.reuters.com - October 11 at 9:02 PM
BRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset ManagementBRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management
www.reuters.com - October 11 at 4:00 PM
Marathon Asset Management and ADMA Biologics Complete $30 Million Debt RefinancingMarathon Asset Management and ADMA Biologics Complete $30 Million Debt Refinancing
finance.yahoo.com - October 11 at 4:00 PM
$6.86 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter$6.86 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - October 8 at 1:28 AM
ETFs with exposure to ADMA Biologics, Inc. : September 28, 2017ETFs with exposure to ADMA Biologics, Inc. : September 28, 2017
finance.yahoo.com - October 2 at 3:16 PM
ADMA Biologics (ADMA) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowADMA Biologics (ADMA) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 8:30 PM
ETFs with exposure to ADMA Biologics, Inc. : September 7, 2017ETFs with exposure to ADMA Biologics, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:24 PM
ETFs with exposure to ADMA Biologics, Inc. : September 7, 2017ETFs with exposure to ADMA Biologics, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:23 PM
ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 3:54 PM
ADMA: Second Quarter 2017 Financial Results and Corporate UpdateADMA: Second Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - August 28 at 3:37 PM
ADMA Biologics to Present at Upcoming Investor ConferencesADMA Biologics to Present at Upcoming Investor Conferences
finance.yahoo.com - August 23 at 3:27 PM
$6.81 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter$6.81 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - August 14 at 8:37 AM
ADMA Biologics Inc (NASDAQ:ADMA) Releases  Earnings Results, Misses Expectations By $0.29 EPSADMA Biologics Inc (NASDAQ:ADMA) Releases Earnings Results, Misses Expectations By $0.29 EPS
www.americanbankingnews.com - August 12 at 10:56 AM
ADMA Biologics Inc (ADMA) Expected to Post Earnings of -$0.42 Per ShareADMA Biologics Inc (ADMA) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - August 12 at 4:08 AM
ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 11 at 9:03 PM
Adma Biologics reports 2Q lossAdma Biologics reports 2Q loss
finance.yahoo.com - August 11 at 9:03 PM
ADMA Biologics Inc (ADMA) to Release Quarterly Earnings on ThursdayADMA Biologics Inc (ADMA) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:00 AM
BRIEF-U.S. Patent and Trademark Office issues immunotehrapy patent to Adma BiologicsBRIEF-U.S. Patent and Trademark Office issues immunotehrapy patent to Adma Biologics
www.reuters.com - August 1 at 1:44 AM
ADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic MethodsADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods
finance.yahoo.com - July 31 at 8:43 PM
At the Site of Germany’s Biggest World War II Battle, a Changing View of HistoryAt the Site of Germany’s Biggest World War II Battle, a Changing View of History
www.nytimes.com - July 19 at 1:58 AM
Click to Bid: Feds Selling Big Denver Development Site OnlineClick to Bid: Feds Selling Big Denver Development Site Online
www.wsj.com - July 19 at 1:58 AM
AP Explains: Korean border village, site for rivals talksAP Explains: Korean border village, site for rivals' talks
www.foxnews.com - July 19 at 1:58 AM

Social Media

Financials

Chart

ADMA Biologics (NASDAQ ADMA) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.